Market News Comments

Genzyme (GENZ)

Genzyme Corp. (NASDAQ: GENZ) today reported that third-quarter revenue was $1.06 billion, compared with $1.16 billion in the same period a year ago. Results reflect the impact of the temporary interruption in production of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) associated with the remediation of the company’s Allston manufacturing facility. GAAP net income was $16.0 million, or $0.06 per diluted share, compared with $119.6 million, or $0.42 per diluted share, in the third quarter of 2008. Non-GAAP net income was $83.9 million, or $0.31 per diluted share, compared with $151.4 million, or $0.53 per diluted share, in the same period last year. Non-GAAP net income excludes purchase accounting and inventory step-up associated with the acquisition of Bayer oncology assets, and stock compensation.
The company's CEO said that during the next 12 months "we will invest in our existing business and pipeline, while making changes to become stronger and build for our future.”

Oct 21 · 10:12:00 AM · Source: Business Wire
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Enter your comment below and click Submit:

Copyright © 2010 MarketBeast.com.
All rights reserved.